Scholarlink

<p>Lung squamous cell carcinoma (LUSC) is a lethal malignancy with a stark lack of targeted therapies, demanding the identification of novel molecular drivers. Here, we identify Protein Phosphatase 1 Regulatory Subunit 14C (PPP1R14C), an endogenous inhibitor of Protein Phosphatase 1 (PP1), as a pivotal oncogenic driver in LUSC. Integrative multi-omics analyses revealed consistent PPP1R14C overexpression in LUSC, which correlated with advanced tumor stage and poor patient survival. Mechanistically, we establish that the transcription factor KLF7 directly binds the PPP1R14C promoter to drive its expression. We demonstrate that PPP1R14C executes its pro-tumorigenic function by physically interacting with and inhibiting the PP1 catalytic subunit, thereby preventing the dephosphorylation and inactivation of CDK1. This sustained CDK1 hyperactivation fuels LUSC cell proliferation, invasion, and in vivo tumorigenesis. Critically, pharmacological inhibition of CDK1 completely abrogates the oncogenic phenotypes conferred by PPP1R14C. Our findings delineate a novel and actionable KLF7–PPP1R14C–PP1–CDK1 signaling cascade essential for LUSC pathogenesis, positioning PPP1R14C as both a prognostic biomarker and a compelling therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcriptional activation of PPP1R14C by KLF7 unleashes CDK1 activity to promote lung squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Lihua Xing,
  • Chunluan Yuan,
  • Xiaozhu Shen,
  • Kun Xiao

摘要

Lung squamous cell carcinoma (LUSC) is a lethal malignancy with a stark lack of targeted therapies, demanding the identification of novel molecular drivers. Here, we identify Protein Phosphatase 1 Regulatory Subunit 14C (PPP1R14C), an endogenous inhibitor of Protein Phosphatase 1 (PP1), as a pivotal oncogenic driver in LUSC. Integrative multi-omics analyses revealed consistent PPP1R14C overexpression in LUSC, which correlated with advanced tumor stage and poor patient survival. Mechanistically, we establish that the transcription factor KLF7 directly binds the PPP1R14C promoter to drive its expression. We demonstrate that PPP1R14C executes its pro-tumorigenic function by physically interacting with and inhibiting the PP1 catalytic subunit, thereby preventing the dephosphorylation and inactivation of CDK1. This sustained CDK1 hyperactivation fuels LUSC cell proliferation, invasion, and in vivo tumorigenesis. Critically, pharmacological inhibition of CDK1 completely abrogates the oncogenic phenotypes conferred by PPP1R14C. Our findings delineate a novel and actionable KLF7–PPP1R14C–PP1–CDK1 signaling cascade essential for LUSC pathogenesis, positioning PPP1R14C as both a prognostic biomarker and a compelling therapeutic target.